As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.
Following the update published on 27 February 2026, we are publishing, for transparency, a copy of an email sent to all MHRA staff by Chief Executive Lawrence Tallon on 11 March 2026, regarding the Pathways clinical trial.
A copy of the email is available here: MHRA staff email - 11 March 2026 (PDF, 125 KB, 2 pages)